New clues to spot a rare blood disorder
NCT ID NCT01713504
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked for new biological markers to help diagnose hypereosinophilic syndrome (HES), a rare condition where too many eosinophils (a type of white blood cell) cause damage. Researchers compared blood samples from 41 people with HES, those with other causes of high eosinophils, and healthy controls. The goal was to find markers that are easier and more informative than current tests, potentially leading to faster and more accurate diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to simpler and more reliable diagnostic tests for hypereosinophilic syndrome, helping doctors identify the disease sooner.
- What could go wrong
- This is a small, completed observational study focused on finding markers, not testing a treatment. The results may not lead to a practical test or change how the disease is managed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
41 people
The number who actually took part.
- Started
-
Jun 2010
- Finished
-
Jul 2015
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * dated and signed informed consent * virale serology negative or negative result less than 6 months * virale serology negative for HBV or vaccinated patient * insured * virale serology negative or negative result less than 6 months * negative pregnancy test or female menopause for at least 1 year Exclusion Criteria: * subject enable adult, under guardianship or under protective measures of justice * Refusal or inability to give informed consent * The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hypereosinophilic syndrome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHRU, Hôpital Claude Huriez
Lille, Nord, 59037, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
- Scientists launch national effort to unravel mysteries of rare blood disorder
- Drug dasatinib tested for rare blood cancers
- New hope for rare blood disorder: drug targets overactive immune cells
- New drug aims to tame rare blood disorder flares
- New hope for kids with rare blood disorder: drug may cut flares and steroid use